Galapagos achieves multiple milestones in rheumatoid arthritis
alliance
(Thomson Reuters ONE) - Mechelen, Belgium; 3 December 2009 - Galapagos NV (Euronext: GLPG)announced today achievement of multiple milestones under its allianceagreement in rheumatoid arthritis. The milestones trigger a cashpayment of ?10.2 million to Galapagos.In October 2007, Galapagos announced an alliance agreement withJanssen Pharmaceutica NV (Janssen) providing Janssen with optionrights to acquire worldwide, commercial licenses to novel smallmolecules from up to 12 of Galapagos' internal programs involvingrheumatoid arthritis therapeutic targets. The milestones announcedtoday are the result of several of these programs reaching the nextphase of medicinal chemistry optimization."We are pleased that the molecules derived under the rheumatoidarthritis alliance have met the agreed upon criteria," said Onno vande Stolpe, CEO of Galapagos. "Galapagos continues to deliver highquality research and remains on course for achieving its goals forthe year."About GalapagosGalapagos (Euronext: GLPG; OTC: GLPYY) is a drug discovery anddevelopment company with small molecule programs in bone and jointdiseases, bone metastasis, cachexia, anti-infectives and metabolicdiseases. It has established risk sharing alliances withGlaxoSmithKline, Lilly and Merck and Co. Through an alliance withMorphoSys, Galapagos is also developing new antibody therapies inbone and joint diseases. Its division BioFocus offers a full suiteof target-to-drug discovery products and services to pharmaceuticaland biotech companies and to patient foundations, encompassing targetdiscovery and validation, screening and drug discovery through todelivery of pre-clinical candidates. Galapagos currently employs 495people and operates facilities in six countries, with globalheadquarters in Mechelen, Belgium. More info at: www.glpg.com.CONTACTGalapagos NVOnno van de Stolpe, CEOTel: +31 6 2909 8028ir(at)glpg.comThis release may contain forward-looking statements, including,without limitation, statements containing the words "believes,""anticipates," "expects," "intends," "plans," "seeks," "estimates,""may," "will," "could," "stands to," and "continues," as well assimilar expressions. Such forward-looking statements may involveknown and unknown risks, uncertainties and other factors which mightcause the actual results, financial condition, performance orachievements of Galapagos, or industry results, to be materiallydifferent from any historic or future results, financial conditions,performance or achievements expressed or implied by suchforward-looking statements. Given these uncertainties, the reader isadvised not to place any undue reliance on such forward-lookingstatements. These forward-looking statements speak only as of thedate of publication of this document. Galapagos expressly disclaimsany obligation to update any such forward-looking statements in thisdocument to reflect any change in its expectations with regardthereto or any change in events, conditions or circumstances on whichany such statement is based, unless required by law or regulation.This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 03.12.2009 - 07:31 Uhr
Sprache: Deutsch
News-ID 9187
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 520 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Galapagos achieves multiple milestones in rheumatoid arthritis
alliance"
steht unter der journalistisch-redaktionellen Verantwortung von
Galapagos NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
